HomeCompareCNCE vs SPHD

CNCE vs SPHD: Dividend Comparison 2026

CNCE yields 23.89% · SPHD yields 4.33%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CNCE wins by $65.9K in total portfolio value
10 years
CNCE
CNCE
● Live price
23.89%
Share price
$8.37
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$92.5K
Annual income
$10,014.51
Full CNCE calculator →
SPHD
SPHD
● Live price
4.33%
Share price
$49.34
Annual div
$2.14
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.5K
Annual income
$571.32
Full SPHD calculator →

Portfolio growth — CNCE vs SPHD

📍 CNCE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCNCESPHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CNCE + SPHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CNCE pays
SPHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CNCE
Annual income on $10K today (after 15% tax)
$2,031.06/yr
After 10yr DRIP, annual income (after tax)
$8,512.33/yr
SPHD
Annual income on $10K today (after 15% tax)
$367.92/yr
After 10yr DRIP, annual income (after tax)
$485.62/yr
At 15% tax rate, CNCE beats the other by $8,026.71/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CNCE + SPHD for your $10,000?

CNCE: 50%SPHD: 50%
100% SPHD50/50100% CNCE
Portfolio after 10yr
$59.5K
Annual income
$5,292.92/yr
Blended yield
8.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CNCE right now

CNCE
Analyst Ratings
16
Buy
1
Hold
Consensus: Buy
Altman Z
2.4
Piotroski
1/9
SPHD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CNCE buys
0
SPHD buys
0
No recent congressional trades found for CNCE or SPHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCNCESPHD
Forward yield23.89%4.33%
Annual dividend / share$2.00$2.14
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$92.5K$26.5K
Annual income after 10y$10,014.51$571.32
Total dividends collected$57.3K$5.1K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CNCE vs SPHD ($10,000, DRIP)

YearCNCE PortfolioCNCE Income/yrSPHD PortfolioSPHD Income/yrGap
1← crossover$13,089$2,389.49$11,133$432.85+$2.0KCNCE
2$16,929$2,923.10$12,363$450.36+$4.6KCNCE
3$21,647$3,533.17$13,695$467.39+$8.0KCNCE
4$27,385$4,222.32$15,138$483.90+$12.2KCNCE
5$34,294$4,992.02$16,697$499.88+$17.6KCNCE
6$42,537$5,842.50$18,382$515.31+$24.2KCNCE
7$52,287$6,772.75$20,198$530.17+$32.1KCNCE
8$63,728$7,780.57$22,157$544.46+$41.6KCNCE
9$77,051$8,862.62$24,266$558.18+$52.8KCNCE
10$92,459$10,014.51$26,536$571.32+$65.9KCNCE

CNCE vs SPHD: Complete Analysis 2026

CNCEStock

Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company's lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.

Full CNCE Calculator →

SPHDETF

The Invesco S&P 500 High Dividend Low Volatility ETF (Fund) is based on the S&P 500 Low Volatility High Dividend Index (Index). The Fund will invest at least 90% of its total assets in common stocks that comprise the Index. Standard & Poor's compiles, maintains and calculates the Index, which is composed of 50 securities traded on the S&P 500 Index that historically have provided high dividend yields and low volatility. The Fund and the Index are rebalanced and reconstituted semi-annually, in January and July.

Full SPHD Calculator →
📬

Get this CNCE vs SPHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CNCE vs SCHDCNCE vs JEPICNCE vs OCNCE vs KOCNCE vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.